Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease

References

• Wagner M, Wanner C, Kotseva K, et al. Prevalence of chronic kidney disease and its determinants in coronary heart disease patients in 24 European countries: insights from the EUROASPIRE IV survey of the European Society of Cardiology. Eur J Prev Cardiol. 2017;24(11):1168–1180.
   PubMed Web of Science ®Google Scholar
• Cai Q, Mukku VK, Ahmad M., et al. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rev. 2013;9(4):331–339.
   PubMedGoogle Scholar
• Tsiachris D, Tsioufis C, Mazzone P, et al. Atrial fibrillation and chronic kidney disease in hypertension: a common and dangerous triad. Curr Vasc Pharmacol. 2015;13(1):111–120.
   PubMed Web of Science ®Google Scholar
• Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848–1853.
   PubMed Web of Science ®Google Scholar
• Kulkarni N, Gukathasan N, Sartori S, et al. Chronic kidney disease and atrial fibrillation: A contemporary overview. J Atr Fibrillation. 2012;5(1):448.
   PubMedGoogle Scholar
• Nayak-Rao S, Shenoy MP. Stroke in patients with chronic kidney disease: how do we approach and manage it? Indian J Nephrol. 2017;27(3):167–171.
   PubMedGoogle Scholar
• Cherng YG, Lin CS, Shih CC, et al. Stroke risk and outcomes in patients with chronic kidney disease or end-stage renal disease: two nationwide studies. PLoS One. 2018;13(1):e0191155.
   PubMed Web of Science ®Google Scholar
• Dad T, Weiner DE. Stroke and chronic kidney disease: epidemiology, pathogenesis, and management across kidney disease stages. Semin Nephrol. 2015;35(4):311–322.
   PubMed Web of Science ®Google Scholar
• Garimella PS, Hirsch AT. Peripheral artery disease and chronic kidney disease: clinical synergy to improve outcomes. Adv Chronic Kidney Dis. 2014;21(6):460–471.
   PubMed Web of Science ®Google Scholar
• O'Hare AM, Glidden DV, Fox CS, et al. High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the national health and nutrition examination survey 1999–2000. Circulation. 2004;109(3):320–323.
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg. 2009;23(5):690–699.
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Koupidis SA, Tzovaras AA, et al. Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures. Int Urol Nephrol. 2011;43(1):143–145.
   PubMed Web of Science ®Google Scholar
• Chen HY, Wei F, Wang LH, et al. Abnormal ankle-brachial index and risk of cardiovascular or all-cause mortality in patients with chronic kidney disease: a meta-analysis. J Nephrol. 2017;30(4):493–501.
   PubMed Web of Science ®Google Scholar
• Smith ER. Vascular calcification in Uremia: new-age concepts about an old-age problem. Methods Mol Biol. 2016;1397:175–208.
   PubMedGoogle Scholar
• Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int. 2014;2014:1–21.
   PubMedGoogle Scholar
• Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56–61.
   PubMed Web of Science ®Google Scholar
• Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs. World J Nephrol. 2014;3(4):156–168.
   PubMedGoogle Scholar
• Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13(8):823–833.
   PubMed Web of Science ®Google Scholar
• Garimella PS, Hart PD, O'Hare A, et al. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. Am J Kidney Dis. 2012;60(4):641–654.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Perez-Martinez P, Mikhailidis DP. Homocysteine and non-cardiac vascular disease. Curr Pharm Des. 2017;23(22):3224–3232.
   PubMed Web of Science ®Google Scholar
• Alizadeh S, Ahmadi M, Ghorbani Nejad B, et al. Metabolic syndrome and its components are associated with increased chronic kidney disease risk: evidence from a meta-analysis on 11 109 003 participants from 66 studies. Int J Clin Pract. 2018 May 23;72:e13201. Epub ahead of print.
   Web of Science ®Google Scholar
• Maric-Bilkan C. Obesity and diabetic kidney disease. Med Clin North Am. 2013;97(1):59–74.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Purrello F, Tsioufis C, et al. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1243–1260.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol. 2014;29(4):389–395.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. ESC scientific document group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017;23:1–87.
   PubMed Web of Science ®Google Scholar
• Tannock L. Dyslipidemia in Chronic Kidney Disease 2018 Jan 22. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext. [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Available from http://www.ncbi.nlm.nih.gov/books/NBK305899/
   Google Scholar
• O'Lone E, Viecelli AK, Craig JC, et al. Cardiovascular outcomes reported in hemodialysis trials. J Am Coll Cardiol. 2018;71(24):2802–2810.
   PubMed Web of Science ®Google Scholar
• Wanner C, Schmidt KR, Krane V. Results of the 4D study: ten years of follow-up? Clin Exp Nephrol. 2014;18(2):274–277.
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, März W, et al. German diabetes and dialysis study investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248.
   PubMed Web of Science ®Google Scholar
• Fellström BC, Jardine AG, Schmieder RE, et al. AURORA study group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C, et al. SHARP investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192.
   PubMed Web of Science ®Google Scholar
• Haynes R, Lewis D, Emberson J, et al. SHARP collaborative group; SHARP collaborative group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825–1833.
   PubMed Web of Science ®Google Scholar
• Wanner C, Tonelli M. Kidney disease: improving global outcomes lipid guideline development work group members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85(6):1303–1309.
   PubMed Web of Science ®Google Scholar
• Heine GH, Rogacev KS, Weingärtner O, et al. Still a reasonable goal: targeting cholesterol in dialysis and advanced chronic kidney disease patients. Semin Dial. 2017;30(5):390–394.
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Žutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.
   PubMed Web of Science ®Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, et al. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117(9):1444–1448.
   PubMed Web of Science ®Google Scholar
• Puri R, Nissen SE, Shao M, et al. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: implications for coronary atheroma progression and cardiovascular events. Eur J Prev Cardiol. 2016;23(5):474–485.
   PubMed Web of Science ®Google Scholar
• Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 2012;51(4):314–324.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem. 2014;21(25):2917–2926.
   PubMed Web of Science ®Google Scholar
• Qin X, Dong H, Fang K, et al. The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2017;33:6.
   Web of Science ®Google Scholar
• Su X, Zhang L, Lv J, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):881–892.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu P, Zhang J, et al. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res. 2016;105:74–83.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–275.
   PubMed Web of Science ®Google Scholar
• Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Banach M, Nikfar S, et al. Lipid and blood pressure meta-analysis collaboration group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168(6):5437–5447.
   PubMed Web of Science ®Google Scholar
• Geng Q, Ren J, Song J, et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014;114(4):562–570.
   PubMed Web of Science ®Google Scholar
• Sanguankeo A, Upala S, Cheungpasitporn W, et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. PLoS One. 2015;10(7):e0132970.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Nikfar S, Salari P, et al. Lipid and blood pressure meta-analysis collaboration group. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29(5):435–451.
   PubMed Web of Science ®Google Scholar
• Mathew RO, Bangalore S, Lavelle MP, et al. Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a review. Kidney Int. 2017;91(4):797–807.
   PubMed Web of Science ®Google Scholar
• Michos ED, Blaha MJ, Blumenthal RS. Use of the coronary artery calcium score in discussion of initiation of statin therapy in primary prevention. Mayo Clin Proc. 2017;92(12):1831–1841.
   PubMed Web of Science ®Google Scholar
• Lee SE, Chang HJ, Sung JM, et al. Effects of Statins on coronary atherosclerotic Plaques: the PARADIGM study. JACC Cardiovasc Imaging. 2018;11(10):1475–1484.
   PubMed Web of Science ®Google Scholar
• Lee SE, Sung JM, Andreini D, et al. J. differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: the progression of atheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging (PARADIGM) study. Eur Heart J Cardiovasc Imaging. 2019 Feb 20. Epub ahead of print.
   Google Scholar
• Du X, Zhang S, Liu L. Statin therapy contributes to plaque-stability by increasing the presence of calcification of plaque. Int J Cardiol. 2018;271:24.
   PubMed Web of Science ®Google Scholar
• Chen Z, Qureshi AR, Parini P, et al. Does statins promote vascular calcification in chronic kidney disease? Eur J Clin Invest. 2017;47(2):137–148.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Granillo GA, Carrascosa P, Bruining N. Progression of coronary artery calcification at the crossroads: sign of progression or stabilization of coronary atherosclerosis? Cardiovasc Diagn Ther. 2016;6(3):250–258.
   PubMed Web of Science ®Google Scholar
• Lioufas N, Hawley CM, Cameron JD, et al. Chronic kidney disease and pulse wave velocity: a narrative review. Int J Hypertens. 2019;2019:9189362.
   PubMed Web of Science ®Google Scholar
• Chen SC, Huang JC, Su HM, et al. Prognostic cardiovascular markers in chronic kidney disease. Kidney Blood Press Res. 2018;43(4):1388–1407.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European society of cardiology working group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) society. Atherosclerosis. 2015;241(2):507–532.
   PubMed Web of Science ®Google Scholar
• Reklou A, Katsiki N, Karagiannis A, et al. Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk?. Curr Vasc Pharmacol. 2019 Jan 20. Epub ahead of print.
   PubMedGoogle Scholar
• Papademetriou V, Katsiki N, Doumas M, et al. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr Pharm Des. 2014;20(40):6339–6349.
   PubMed Web of Science ®Google Scholar
• Koumaras C, Tziomalos K, Stavrinou E, et al. Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. J Am Soc Hypertens. 2014;8(2):74–82.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Imprialos K. Editorial: arterial stiffness, central haemodynamics and non-alcoholic fatty liver disease: links with cardiovascular risk and effects of drug treatment. Curr Vasc Pharmacol. 2018;16(4):401–404.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018;79:64–76.
   PubMed Web of Science ®Google Scholar
• Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 2017;67(6):1274–1280.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21(22):6820–6834.
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Perez-Martinez P, Anagnostis P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018;16(3):219–227.
   PubMed Web of Science ®Google Scholar
• Chinnadurai R, Ritchie J, Green D, et al. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant. 2019;34(3):449–457.
   PubMed Web of Science ®Google Scholar
• Paik J, Golabi P, Younoszai Z, et al. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int. 2019;39(2):342–352.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism. 2017;71:17–32.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Editorial: DM. Recent news on statins for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Curr Vasc Pharmacol. 2018;16(2):104–106.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Mikhailidis DP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications. 2017;31(3):521–522.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123.
   PubMed Web of Science ®Google Scholar
• Sun G, Chen P, Wang K, et al. Contrast-induced nephropathy and long-term mortality after percutaneous coronary intervention in patients with acute myocardial infarction. Angiology. 2019;70:621–626.
   Google Scholar
• Cury MVM, Matielo MF, Brochado Neto FC, et al. The incidence, risk factors, and outcomes of contrast-induced nephropathy in patients with critical limb ischemia following lower limb angiography. Angiology. 2018;69(8):700–708.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Contrast-induced nephropathy: an “All or None” phenomenon? Angiology. 2015;66(6):508–513.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Fonseca V, Mikhailidis DP. Contrast-induced acute kidney injury in diabetes mellitus: clinical relevance and predisposing factors. Could statins be of benefit? J Diabetes Complications. 2018;32(11):982–984.
   PubMed Web of Science ®Google Scholar
• Leung KC, Pannu N, Tan Z, et al. APPROACH and AKDN Investigators. Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome. Clin J Am Soc Nephrol. 2014;9(11):1840–1848.
   PubMed Web of Science ®Google Scholar
• Zhou X, Dai J, Xu X, et al. Comparative efficacy of statins for prevention of contrast-induced acute kidney injury in patients with chronic kidney disease: a network meta-analysis. Angiology. 2019;70(4):305–316.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Ezetimibe and low-density lipoprotein subfractions: an ongoing debate. Curr Med Res Opin. 2011;27(3):693–695.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des. 2013;19(17):3107–3114.
   PubMed Web of Science ®Google Scholar
• Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract. 2013;100(1):46–52.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Mikhailidis DP. More news from IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). Hormones (Athens). 2016;15(1):5–7.
   PubMedGoogle Scholar
• Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother. 2016;17(3):369–380.
   PubMed Web of Science ®Google Scholar
• Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: more than cholesterol lowering? Curr Med Res Opin. 2010;26(10):2517–2520.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato E, Amaha M, et al. Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. J Int Med Res. 2012;40(2):798–803.
   PubMed Web of Science ®Google Scholar
• Morita T, Morimoto S, Nakano C, et al. Renal and vascular protective effects of ezetimibe in chronic kidney disease. Intern Med. 2014;53(4):307–314.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Stanifer JW, Charytan DM, White J, et al. Benefit of Ezetimibe added to simvastatin in reduced kidney function. J Am Soc Nephrol. 2017;28(10):3034–3043.
   PubMed Web of Science ®Google Scholar
• Yagi S, Akaike M, Aihara K, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb. 2010;17(2):173–180.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61(1):58–61.
   PubMed Web of Science ®Google Scholar
• Kubo M, Miyoshi T, Kimura T, et al. Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study. Am J Cardiovasc Drugs. 2014;14(5):387–392.
   PubMed Web of Science ®Google Scholar
• Torimoto K, Okada Y, Mori H, et al. Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 2013;12:137.
   PubMed Web of Science ®Google Scholar
• Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010;8(6):820–830.
   PubMed Web of Science ®Google Scholar
• Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb. 2011;18(12):1080–1089.
   PubMed Web of Science ®Google Scholar
• Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2010;17(10):1070–1076.
   PubMed Web of Science ®Google Scholar
• Lee HY, Jun DW, Kim HJ, et al. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med. 2019;34(2):296–304.
   PubMed Web of Science ®Google Scholar
• Simon TG, Corey KE, Chung RT, et al. Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: the potential role of Ezetimibe. Dig Dis Sci. 2016;61(12):3425–3435.
   PubMed Web of Science ®Google Scholar
• Nakade Y, Murotani K, Inoue T, et al. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47(13):1417–1428.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013;19(17):3124–3131.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Ting RD, Keech AC, Drury PL, et al. FIELD study investigators. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012;35(2):218–225.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Mikhailidis DP, Elisaf M. Summarizing the FIELD study: lessons from a ‘negative’ trial. Expert Opin Pharmacother. 2013;14(18):2601–2610.
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert Opin Drug Metab Toxicol. 2015;11(6):851–855.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A. Exploring the management of statin intolerant patients: 2016 and beyond. Curr Vasc Pharmacol. 2016;14(6):523–533.
   PubMed Web of Science ®Google Scholar
• Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60(20):2061–2071.
   PubMed Web of Science ®Google Scholar
• Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep. 2009;11(5):338–342.
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: an overview. Eur J Clin Invest. 2013;43(5):522–531.
   PubMed Web of Science ®Google Scholar
• Kasiske B, Cosio FG, Beto J, et al. National kidney foundation. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the managing dyslipidemias in chronic kidney disease work group of the national kidney foundation kidney disease outcomes quality initiative. Am J Transplant. 2004;4(Suppl 7):13–53.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C–18C.
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Garg J, Shah N, et al. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol. 2017;9(2):76–91.
   PubMed Web of Science ®Google Scholar
• Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Mikhailidis DP, et al. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism. 2017;74:43–46.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Lipids: a personal view of the past decade. Hormones (Athens). 2018;17(4):461–478.
   PubMedGoogle Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER steering committee and investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397–1408.
   PubMed Web of Science ®Google Scholar
• [cited 2019 May 14]. Available from: https://www.amgen.com/media/news-releases/2018/10/amgen-announces-new-fourier-analysis-showing-benefit-with-repatha-evolocumab-in-highrisk-patients-with-established-cardiovascular-disease-and-chronic-kidney-disease/Last
   Google Scholar
• Zheng-Lin B, Ortiz A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs. 2018;78(2):215–229.
   PubMed Web of Science ®Google Scholar
• Shrestha P, van de Sluis B, Dullaart RPF, et al. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal. 2019;55:53–64.
   PubMed Web of Science ®Google Scholar
• Del Vecchio L, Baragetti I, Locatelli F. New agents to reduce cholesterol levels: implications for nephrologists. Nephrol Dial Transplant. 2019 Feb 11. Epub ahead of print.
   Google Scholar
• Pei J, Zhao Y, Huang L, et al. The effect of n-3 polyunsaturated fatty acids on plasma lipids and lipoproteins in patients with chronic renal failure: a meta-analysis of randomized controlled trials. J Ren Nutr. 2012;22(6):525–532.
   PubMed Web of Science ®Google Scholar
• Xu T, Sun Y, Sun W, et al. Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis. Sci Rep. 2016;6:39346.
   PubMed Web of Science ®Google Scholar
• Chi H, Lin X, Huang H, et al. Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Arch Med Res. 2014;45(6):469–477.
   PubMed Web of Science ®Google Scholar
• Sørensen GV, Svensson M, Strandhave C, et al. The effect of n-3 fatty acids on small dense low-density lipoproteins in patients with end-stage renal disease: a randomized placebo-controlled intervention study. J Ren Nutr. 2015;25(4):376–380.
   PubMed Web of Science ®Google Scholar
• Ide K, Koshizaka M, Tokuyama H, et al. N-3 polyunsaturated fatty acids improve lipoprotein particle size and concentration in Japanese patients with type 2 diabetes and hypertriglyceridemia: a pilot study. Lipids Health Dis. 2018;17(1):51.
   PubMedGoogle Scholar
• Lee SM, An WS. Cardioprotective effects of ω −3 PUFAs in chronic kidney disease. Biomed Res Int. 2013;2013:712949.
   PubMed Web of Science ®Google Scholar
• Abdelhamid AS, Martin N, Bridges C, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:CD012345.
   PubMedGoogle Scholar
• Perez-Martinez P, Katsiki N, Mikhailidis DP. The role of n-3 fatty acids in cardiovascular disease: back to the future. Angiology. 2019 Apr 9;3319719842005. Epub ahead of print.
   PubMedGoogle Scholar
• Bhatt DL, Steg PG, Miller M, et al. REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Saglimbene VM, Wong G, van Zwieten A, et al. Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019 Mar 14. Epub ahead of print
   Google Scholar
• Friedman AN, Yu Z, Tabbey R, et al. Inverse relationship between long-chain n-3 fatty acids and risk of sudden cardiac death in patients starting hemodialysis. Kidney Int. 2013;83(6):1130–1135.
   PubMed Web of Science ®Google Scholar
• Tam KW, Wu MY, Siddiqui FJ, et al. Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease. Cochrane Database Syst Rev. 2018;11:CD011353.
   PubMedGoogle Scholar
• Hu J, Liu Z, Zhang H. Omega-3 fatty acid supplementation as an adjunctive therapy in the treatment of chronic kidney disease: a meta-analysis. Clinics (Sao Paulo). 2017;72(1):58–64.
   PubMed Web of Science ®Google Scholar
• Hoogeveen EK, Geleijnse JM, Kromhout D, et al. Effect of omega-3 fatty acids on kidney function after myocardial infarction: the alpha omega trial. Clin J Am Soc Nephrol. 2014;9(10):1676–1683.
   PubMed Web of Science ®Google Scholar
• Han E, Yun Y, Kim G, et al. Effects of omega-3 fatty acid supplementation on diabetic nephropathy progression in patients with diabetes and hypertriglyceridemia. PLoS One. 2016;11(5):e0154683.
   PubMed Web of Science ®Google Scholar
• Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease: why, who and when? Expert Opin Pharmacother. 2010;11(16):2665–2674.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Triposkiadis F, Giannoukas AD, et al. Statin loading in cardiovascular surgery: never too early to treat. Curr Opin Cardiol. 2018;33(4):436–443.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Yajima J, Oikawa Y, et al. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels. 2014;29(1):21–28.
   PubMed Web of Science ®Google Scholar
• Washam JB, Herzog CA, Beitelshees AL, et al. American heart association clinical pharmacology committee of the council on clinical cardiology, council on cardiovascular surgery and anesthesia, council on functional genomics and translational biology, council on the kidney in cardiovascular disease, and council on quality of care and outcomes research. pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American heart association. Circulation. 2015;131(12):1123–1149.
   PubMedGoogle Scholar
• Ge Z, Baber U, Claessen BE, et al. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019;93(3):E112–E119.
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. International Lipid Expert Panel (ILEP). The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72(1):96–118.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Colletti A, Bajraktari G, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965–1005.
   PubMed Web of Science ®Google Scholar
• Dujovne CA. Red yeast rice preparations: are they suitable substitutions for Statins? Am J Med. 2017;130(10):1148–1150.
   PubMed Web of Science ®Google Scholar
• [cited 2019 May 14]. https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2018.5368
   Google Scholar
• Fogacci F, Banach M, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) group; International Lipid Expert Panel (ILEP). Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1–16.
   PubMed Web of Science ®Google Scholar
• Peng D, Fong A, Pelt AV. Original research: the effects of red yeast rice supplementation on cholesterol levels in adults. Am J Nurs. 2017;117(8):46–54.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Banach M, Sahebkar A, et al. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opin Pharmacother. 2019;20(7):791–803.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. CLEAR harmony trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–1032.
   PubMed Web of Science ®Google Scholar
• Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Rizzo M, Mikhailidis DP, et al. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015;24(10):1389–1398.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ray KK, Johansson JO, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18(2):109–115.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Wolski K, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016;16(1):55–65.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57(9):1111–1119.
   PubMed Web of Science ®Google Scholar
• Di Bartolo BA, Scherer DJ, Nicholls SJ. Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. Arch Med Sci. 2016;12(6):1302–1307.
   PubMed Web of Science ®Google Scholar
• Gilham D, Wasiak S, Tsujikawa LM, et al. P. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48–57.
   PubMed Web of Science ®Google Scholar
• Wasiak S, Tsujikawa LM, Halliday C, et al. Benefit of Apabetalone on Plasma Proteins in Renal Disease. Kidney Int Rep. 2017;3(3):711–721.
   PubMed Web of Science ®Google Scholar
• Kulikowski E, Halliday C, Johansson J, et al. Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease. Kidney Blood Press Res. 2018;43(2):449–457.
   PubMed Web of Science ®Google Scholar
• [cited 2019 May 14]. https://clinicaltrials.gov/ct2/show/NCT02586155
   Google Scholar
• Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease. Nephrol Dial Transplant. 2018;33(11):1875–1886.0.
   PubMed Web of Science ®Google Scholar